This content is machine translated Endometrial Cancer Immunological drivers and new therapeutic pathways Endometrial carcinoma is increasingly becoming the focus of modern tumor immunology as an immunologically characterized tumor disease. Molecular subtypes, microbiome interactions and a highly dynamic tumor immunological microenvironment are opening...…
View Post 4 min This content is machine translated HER2+ early breast cancer DESTINY-Breast11 – neoadjuvant T-DXd without anthracyclines The phase III DESTINY-Breast11 trial shows that neoadjuvant trastuzumab deruxtecan (T-DXd) could provide an anthracycline-free treatment option for HER2-positive early breast cancer. The results suggest an effective and better tolerated...…
